Savient Pharmaceuticals, Inc. (SVNT) Reports First Quarter 2013 Financial Results
5/15/2013 7:11:20 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Drug Sales Drop
3/20/2013 8:00:30 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Reports Fourth Quarter and Year-End 2012 Financial Results
3/19/2013 7:05:35 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
2/26/2013 9:47:36 AM
More...
|
Sobi and Savient Pharmaceuticals, Inc. (SVNT) Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.
2/19/2013 11:31:07 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Announces the Election of Genzyme Corporation (GENZ) CEO Dr. David Meeker to its Board of Directors
1/8/2013 7:25:45 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) to Present at the 31st Annual J.P. Morgan Healthcare Conference
1/4/2013 7:21:03 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Announces the Election of Robert G. Savage to Its Board of Directors
12/5/2012 9:27:34 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Release: New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
11/13/2012 10:32:10 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Release: New Data Published in Annals of the Rheumatic Diseases Confirm Long-Term Safety and Efficacy of KRYSTEXXA® for the Treatment of Refractory Chronic Gout
11/12/2012 11:16:39 AM
More...
|
|